20
Participants
Start Date
October 29, 2012
Primary Completion Date
June 29, 2016
Study Completion Date
June 29, 2016
FK949E
Oral tablet
Site JP00024, Chiba
Site JP00023, Fukuoka
Site JP00025, Fukuoka
Site JP00015, Fukushima
Site JP00029, Fukushima
Site JP00001, Hokkaido
Site JP00002, Hokkaido
Site JP00003, Hokkaido
Site JP00004, Hokkaido
Site JP00005, Hokkaido
Site JP00006, Hokkaido
Site JP00007, Hokkaido
Site JP00008, Hokkaido
Site JP00009, Hokkaido
Site JP00010, Hokkaido
Site JP00011, Hokkaido
Site JP00012, Hokkaido
Site JP00013, Hokkaido
Site JP00028, Hyōgo
Site JP00031, Ibaraki
Site JP00017, Kanagawa
Site JP00032, Kanagawa
Site JP00019, Kumamoto
Site JP00018, Kyoto
Site JP00014, Osaka
Site JP00016, Tokyo
Site JP00020, Tokyo
Site JP00021, Tokyo
Site JP00022, Tokyo
Site JP00026, Tokyo
Site JP00027, Tokyo
Site JP00030, Tottori
Lead Sponsor
Astellas Pharma Inc
INDUSTRY